Corcept Therapeutics

Cortisol is the hormone that keeps you alive under stress. It floods the bloodstream in a crisis, sharpens attention, mobilizes energy and quiets inflammation. It is also, when it runs too high for too long, a slow saboteur - wrecking metabolism, feeding tumors, unsettling mood and raising blood pressure. Most of medicine treats the downstream damage. Corcept Therapeutics was built on a different premise: turn the hormone down at the point where it acts.

The idea began, appropriately, at a moment of pressure. In the late 1990s, Joseph K. Belanoff was a psychiatry resident at Stanford University, working alongside Alan F. Schatzberg, chairman of the department. Their research pointed to a new use for a class of medication that blocked cortisol at one of its two receptors - the glucocorticoid receptor. In May 1998 they turned that intellectual property into a company. Belanoff became chief executive in 1999, a job he still holds more than a quarter-century later. That continuity is rare in biotechnology, and it explains a lot about how Corcept operates.

What Corcept actually does

Corcept discovers, develops and sells medicines that treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of cortisol. The scientific through-line is narrow and deliberate: nearly everything the company makes acts on the same receptor, blocking cortisol's activity without disturbing the body's other hormone systems, such as the progesterone receptor. Where other biotechs spread bets across many mechanisms, Corcept went deep on one and stayed there.

That focus produced the company's first commercial product. In 2012 the FDA approved Korlym - the first medicine ever cleared in the United States for Cushing's syndrome, a condition in which the body is exposed to dangerously high cortisol. Korlym is a once-daily oral tablet for hyperglycemia secondary to endogenous Cushing's syndrome in adults who have failed surgery or cannot have it. The FDA designated it an Orphan Drug. For a rare disease with roughly 10 to 15 new diagnoses per million people each year - about 3,000 new US patients annually - it was the first approved option where there had been none.

Who its customers are

Corcept's medicines reach patients through specialists: endocrinologists managing Cushing's syndrome and hypercortisolism, and now oncologists treating advanced ovarian cancer. These are not mass-market drugs advertised to consumers. They are prescribed by physicians treating serious, often under-diagnosed conditions, and delivered through specialty pharmacies. The company complements that with investigator-initiated studies and patient-support programs - the connective tissue of a rare-disease business.

The problem it solves

Excess cortisol is both dangerous and easy to miss. Its symptoms - weight gain, diabetes that will not settle, resistant high blood pressure, mood changes - look like a dozen other things. Corcept's newer trials, with names like CATALYST and MOMENTUM, are essentially arguments that hidden cortisol excess is more common than doctors assume, hiding inside difficult-to-control diabetes and treatment-resistant hypertension. If the company is right, the addressable population is far larger than the rare-disease label suggests. The CATALYST trial reported positive results treating patients with hypercortisolism and difficult-to-control diabetes; MOMENTUM probes prevalence in resistant hypertension.

The second act

For years, the interesting question about Corcept was whether cortisol modulation could travel beyond endocrinology. In March 2026 it got an answer. The FDA approved Lifyorli - relacorilant, a next-generation selective glucocorticoid receptor antagonist - in combination with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer in patients who had received prior therapy including bevacizumab. The approval rested on the Phase 3 ROSELLA trial, which showed a 35% reduction in the risk of death and median overall survival of 16.0 months for the combination versus 11.9 months for chemotherapy alone. The same molecular idea that treated a rare hormone disorder had become an approved cancer therapy.

Months later, in June 2026, Corcept resubmitted relacorilant's New Drug Application for Cushing's syndrome - meaning a single compound is being pushed simultaneously toward endocrinology and oncology. Behind it sits a bench of siblings sharing the "-corilant" naming convention: miricorilant in liver disease, dazucorilant in ALS, and exicorilant. It is one idea, fanned out across four therapeutic areas.

How it makes money - and how it differs

Corcept's business model is unusual for a company its size: it is largely self-funded. Rather than living on repeated rounds of dilutive venture capital, it has financed its pipeline from product revenue - primarily Korlym - reinvesting cash flow into research. Revenue reached $761.4 million in 2024, and in 2026 the company raised full-year guidance to between $950 million and $1.05 billion on the strength of the Lifyorli launch. First-quarter 2026 revenue was $164.9 million, up from $157.2 million a year earlier, with a net loss of $31.8 million as commercial and R&D spending ramped for the new launch. The market took notice: the stock roughly doubled in 2026, and Corcept's market capitalization reached about $7.45 billion.

Its competitive position follows from its focus. In Cushing's syndrome it competes with Recordati's Isturisa and Xeris's Recorlev; in ovarian cancer, Lifyorli is measured against standard chemotherapy and other targeted agents. But no rival has spent 25 years building an entire library of molecules around cortisol modulation. That accumulated depth - more than 1,000 compounds, a founder-CEO who never changed the thesis, and orphan-disease expertise most companies avoid - is the moat.

The lesson embedded in Corcept's story is unglamorous. A rare-disease drug that many investors overlooked funded the cancer program that may redefine the company. Depth beat breadth. Patience, in a field addicted to pivots, turned one scientific hunch into a commercial franchise.